ARID2 and colorectal carcinoma: In addition, we found that silencing MUC1-C in (i) NCI-H660 neuroendocrine PC (NEPC) cells (Fig. 1G), (ii) BT-549 triple-negative breast cancer (Supplementary Fig. S1B) and (ii) SW620 colorectal cancer (CRC) (Supplementary Fig. S1C) cells results in downregulation of PBRM1, ARID2, and BRD7.